Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: Who and when

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 787-797

  Bex, Axel ^a   Powles, Tom ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cytoreductive nephrectomy; metastatic; renal cell carcinoma; selection; targeted therapy

Indexed keywords

ALPHA INTERFERON; SUNITINIB;

ADVANCED CANCER; AGE; CANCER PROGNOSIS; COMORBIDITY; CYTOREDUCTIVE SURGERY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SELECTION; REVIEW; RISK FACTOR; TRANSLATIONAL RESEARCH; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; KIDNEY NEOPLASMS; NEPHRECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862861309     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.54     Document Type: Review

References (81)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007).
2. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin. Urol. Oncol. 19(2), 98-102 (2001).
3. Russo P, O'Brien MF. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol. Clin. North Am. 35(4), 679-686 (2001).
4. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
5. Mickisch GH, Garin A, Van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001).
6. Motzer RJ, Bukowski RM, Figlin RA et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 113(7), 1552-1558 (2008).
7. Wood CG. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 13(2 Pt 2), 697s-702s (2001).
8. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin. Cancer Res. 13(2 Pt 2), 693s-696s (2007).
9. Wood CG, Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115(Suppl. 10), 2355-2360 (2009).
10. Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60(3), 448-454 (2011). Meta-analysis of two Phase II trials demonstrating that presurgical therapy with sunitinib can be used to select out those with poor prognosis prior to surgery.
11. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171(3), 1071-1076 (2004).
12. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009).
13. van der Veldt AA, Meijerink MR, van den Eertwegh AJ et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin. Cancer Res. 14(8), 2431-2436 (2008).
14. Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr. Urol. Rep. 13(1), 38-46 (2011).
15. Richey SL, Culp SH, Jonasch E et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann. Oncol. 22(5), 1048-1053 (2011). Retrospective analysis providing important data on survival following targeted therapy without cytoreductive nephrectomy (CN).
16. Zini L, Capitanio U, Perrotte P et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 73(2), 342-346 (2009).
17. Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185(1), 60-66 (2011). Carefully performed retrospective analysis on survival following CN in combination with targeted therapy. Includes stratification by performance.
18. Warren M, Venner PM, North S et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can. Urol. Assoc. J. 3(4), 281-289 (2001).
19. Aben KK, Heskamp S, Janssen-Heijnen ML et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur. J. Cancer 47(13), 2023-2032 (2011). Retrospective population-based analysis on survival following CN. Demonstrates improved survival across all risk scores.
20. Bex A, Jonasch E, Kirkali Z et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur. Urol. 58(6), 819-828 (2010).
21. Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181(2), 518-523 (2009).
22. Bex A, van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta Oncol. 49(4), 520-523 (2010).
23. Johannsen M, Staehler M, Ohlmann CH et al. Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy. Ann. Oncol. 22(3), 657-663 (2011). Retrospective analysis on outcome following cessation of targeted therapy in patients with complete response. Demonstrates the importance of surgery in this setting.
24. Sadeghi S, Albiges L, Wood LS et al. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer doi:10.1002/cncr.26666 (2011) (Epub ahead of print).
25. Griffioen AW, Vyth-Dreese FA. Angiostasis as a way to improve immunotherapy. Thromb. Haemost. 101(6), 1025-1031 (2009).
26. Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 3(1), 77-96 (2011).
27. Blank C, Kuball J, Voelkl S et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119(2), 317-327 (2006).
28. Gajewski TF, Meng Y, Blank C et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
29. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66(7), 3381-3385 (2006).
30. Krambeck AE, Thompson RH, Dong H et al. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl Acad. Sci. USA 103(27), 10391-10396 (2006).
31. Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
32. Desar IM, Jacobs JFM, HulsbergenvandeKaa CA et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer 129(2), 507-512 (2011).
33. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7(1), 41-51 (2007).
34. Ko JS, Rayman P, Ireland J et al. Direct and differential suppression of myeloidderived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70(9), 3526-3536 (2010).
35. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated antiangiogenic therapy. Int. Immunopharmacol. 11(7), 856-861 (2011).
36. Lara PN Jr, Tangen CM, Conlon SJ, Flanigan RC, Crawford ED. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J. Urol. 181(2), 512-516 (2001).
37. Barbastefano J, Garcia JA, Elson P et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 106(9), 1266-1269 (2010). Retrospective study revealing the importance of tumor burden in the decision for CN.
38. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 100(4), 755-759 (2007).
39. Kutikov A, Uzzo RG, Caraway A et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 106(2), 218-223 (2010). Retrospective study analyzing the factors that lead to inability to commence systemic treatment following CN.
40. Abdollah F, Sun M, Thuret R et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann. Surg. Oncol. 18(10), 2988-2996 (2011).
41. O'Malley RL, Brewer KA, Hayn MH et al. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? Urology 78(3), 595-600 (2011).
42. Cloutier V, Capitanio U, Zini L et al. Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur. Urol. 56(6), 998-1003 (2009).
43. Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology 69(5), 835-838 (2007).
44. Bex A, van der Veldt AA, Blank C et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J. Urol. 27(4), 533-539 (2009).
45. Maxwell NJ, Saleem Amer N, Rogers E, Kiely D, Sweeney P, Brady AP. Renal artery embolisation in the palliative treatment of renal carcinoma. Br. J. Radiol. 80(950), 96-102 (2007).
46. Leibovich BC, Cheville JC, Lohse CM et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J. Urol. 174(5), 1759-1763 (2005).
47. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann. Oncol. 13(9), 1460-1468 (2002).
48. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J. Clin. Oncol. 16(6), 2261-2266 (1998).
49. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117(13), 2873-2882 (2011).
50. Karam JA, Rini BI, Varella L et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J. Urol. 185(2), 439-444 (2011).
51. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999).
52. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 22(2), 295-300 (2011).
53. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3), 543-550 (2007).
54. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
55. Culp SH, Tannir NM, Abel EJ et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116(14), 3378-3388 (2010). A prognostic model specifically developed to select for CN. Based on a large database, currently the best available tool to select patients with primary metastatic renal cell carcinoma for surgery.
56. You D, Jeong IG, Ahn JH et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J. Urol. 185(1), 54-59 (2011).
57. Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J. Urol. 178(5), 1896-1900 (2007).
58. Margulis V, Wood CG. Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical therapy? Eur. Urol. 54(3), 480-492 (2008).
59. Amin C, Wallen E, Pruthi RS, Calvo BF, Godley PA, Rathmell WK. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72(4), 864-868 (2008).
60. Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A Phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 78(4), 832-837 (2011).
61. Cowey CL, Amin C, Pruthi RS et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol. 28(9), 1502-1507 (2010).
62. Hellenthal NJ, Underwood W, Penetrante R et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol. 184(3), 859-864 (2010).
63. Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(25), 4076-4081 (2009).
64. Chapin BF, Delacroix SE Jr, Culp SH et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur. Urol. 60(5), 964-971 (2011).
65. Powles T, Kayani I, Blank C et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann. Oncol. 22(5), 1041-1047 (2011).
66. Abel EJ, Culp SH, Tannir NM et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol. 59(1), 10-15 (2011).
67. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol. 60(6), 1273-1279 (2011).
68. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
69. Boleti E, Chowdhury S, Jones R, Crabb S, Sarwar N, Powles T. The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer. Presented at: 2012 Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012.
70. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398-406 (2010).
71. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011).
72. Welti JC, Gourlaouen M, Powles T et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30(10), 1183-1193 (2011).
73. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279), 360-363 (2010).
74. Stewart G, Berney D, Harrison D, Powles T. Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. Presented at: 2012 Genitourinary Cancers Symposium. San Francisco, CA, USA, 2-4 February 2012 (2012).
75. Bex A, Haanen J. Tilting the AXIS towards therapeutic limits in renal cancer. Lancet 378(9807), 1898-1900 (2011).
76. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011).
77. Oudard S. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res. 30(12), 5223-5225 (2010).
78. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int. 108(10), 1556-1563 (2011).
79. Amin A, Dudek A, Logan T et al. A Phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J. Clin. Oncol. 28(Suppl.), 15 (2010) (Abstract 4588). 101 ClinicalTrials.gov. Clinical Trial to Assess the Importance of Nephrectomy (CARMENA). http://clinicaltrials.gov/ct2/show/NCT00930033
80. ClinicalTrials.gov. BMS-936558 (MDX- 1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC). http:// clinicaltrials.gov/ct2/show/NCT01354431
81. ClinicalTrials.gov. IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma. http://clinicaltrials.gov/ct2/show/ NCT01265901